Clinical Trial

Study on the Mechanism of Acquired Resistance of Entrectinib

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 30, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to learn about the mechanism of acquired resistance in first line trearment of ROS1-positive NSCLC with entrectinib. The main question it aims to answer is: what is the acquired resistant mechanism of entrectinib as first line treatment setting in patients? Tissue or blood samples of participants who have already taken entrectinib as their regular medical care for NSCLC will send for Next gene sequencing for genomic profiles and bioinformatic analysis.
Trial Details
NCT Number NCT07199959
Lead Sponsor Fudan University
Collaborators: Ruijin Hospital, The First Affiliated Hospital of Shanghai Jiaotong University
Conditions ROS1 Fusion Positive, Non Small Cell Lung Cancer
Enrollment 38 participants
Start Date 2025-01-15
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-30